PCI Biotech: Bile duct cancer (cholangiocarcinoma) selected as next indication for PCI Biotech. Clinical proof of concept study to start by end of 1H 2013
August 21, 2012 02:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 21 August 2012 - PCI Biotech (PCIB) the...
PCI Biotech: Second quarter and first half year 2012 results
August 21, 2012 01:30 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, Norway, 21 August 2012Please find attached the...
PCI Biotech: Resultatrapport for 2.kvartal og første halvår 2012
August 21, 2012 01:30 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 21.august 2012 Vedlagt er presentasjon og...
PCI Biotech: Invitasjon til presentasjon av resultater for Q2 2012
August 14, 2012 05:03 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} (Lysaker, 14.august 2012) PCI Biotech Holding ASA...
PCI Biotech: Completed inclusion of patients in the phase I/II extension study of Amphinex®
May 29, 2012 07:31 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 29 May 2012 - PCI Biotech (PCIB) the...
PCI Biotech: Fullført inklusjon av pasienter i den utvidede delen av fase I/II-studien av Amphinex®
May 29, 2012 07:31 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 29.mai 2012 - PCI Biotech (PCIB) melder i dag...
PCI Biotech :Første pasient inkludert i fase II-studien av Amphinex® i hode-/halskreftpasienter
May 16, 2012 06:14 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 16.mai 2012 - PCI Biotech (PCIB) melder i dag...
PCI Biotech: First quarter 2012 report
May 08, 2012 02:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, Norway, 08 May 2012.Please find attached the...
PCI Biotech: Resultatrapport for 1.kvartal 2012
May 08, 2012 02:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 08.mai 2012Vedlagt er rapport for første...
PCI Biotech: Annual overview
April 30, 2012 05:03 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Issuers of listed transferable securities are...